Jacobs Levy Equity Management, Inc Aclaris Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 460,842 shares of ACRS stock, worth $774,214. This represents 0.0% of its overall portfolio holdings.
Number of Shares
460,842
Previous 576,042
20.0%
Holding current value
$774,214
Previous $1.43 Million
50.63%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding ACRS
# of Institutions
112Shares Held
92.4MCall Options Held
35.4KPut Options Held
32K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$23.9 Million17.65% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.63MShares$16.2 Million0.03% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$14.9 Million3.69% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD5.05MShares$8.48 Million0.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.97MShares$8.35 Million0.0% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $112M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...